Loading…
PMVP
PMV Pharmaceuticals, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 69353Y103
$1.37-9.27%Price as of Sep 23, 22:31 UTC · updated once a day, after the close
Key metrics
- Market cap
- $73.24M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.0x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.42
- ROE
- -70.93%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.37
- 52-week high
- $1.88
- 52-week low
- $1.02
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -94.4% over 5Y.
today you would have $44.63▼ -95.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $1.25 | $1.51 | $3.10 | $8.70 | $23.10 | $61.51 | |
| P/B | 1.2x | 0.6x | 0.4x | 0.7x | 1.6x | 3.4x | 7.7x |
| EPS | -$1.48 | -$1.14 | -$1.44 | -$1.61 | -$1.28 | -$2.40 | |
| ROE | -30.18% | -74.24% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | $1.72 | — | — | — | -703.68% | $73.28M |
| OMOutset Medical, Inc. | $3.94 | — | 0.8x | — | -59.17% | $74.06M |
| ELTXElicio Therapeutics, Inc. | $2.84 | — | 7.8x | — | -774.56% | $74.64M |
| LONALeonaBio, Inc. | $7.94 |
About the company
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
- 54
- Princeton, United States
Company description provided by Yahoo Finance.